Candel Therapeutics, Inc.

Candel Therapeutics, Inc.

Biotechnology • Healthcare • Needham, MA, United States • CADL (NGM)

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

617 916 5445 117 Kendrick Street, Needham, MA 02494, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Is Candel Therapeutics On The Move With Pipeline Progress And Market Momentum? - RTTNews
RTTNews • Dec 12
Candel Therapeutics, Inc. $CADL is Acorn Capital Advisors LLC's 5th Largest Position - MarketBeat
MarketBeat • Dec 13
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - Yahoo Finance
Yahoo Finance • Jun 2
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
GlobeNewswire • Nov 13
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer - PR Newswire
PR Newswire • Oct 14

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Candel Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Candel Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Candel Therapeutics, Inc. have?
Candel Therapeutics, Inc. has approximately 38 employees.
What industry is Candel Therapeutics, Inc. in?
Candel Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Candel Therapeutics, Inc. a publicly traded company?
Yes, Candel Therapeutics, Inc. is publicly traded under the ticker symbol CADL on the NGM. The company has a market capitalization of approximately $0.33 billion.
Where is Candel Therapeutics, Inc. headquartered?
Candel Therapeutics, Inc. is headquartered in Needham, MA, United States at 117 Kendrick Street, Needham, MA 02494, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.